Joseph P. Hagan Sells 115,290 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Joseph P. Hagan sold 115,290 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $145,265.40. Following the completion of the sale, the chief executive officer now owns 222,572 shares in the company, valued at approximately $280,440.72. This represents a 34.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Regulus Therapeutics Price Performance

RGLS stock opened at $1.28 on Friday. The business has a fifty day moving average price of $1.52 and a 200 day moving average price of $1.58. Regulus Therapeutics Inc. has a fifty-two week low of $1.08 and a fifty-two week high of $3.79. The stock has a market capitalization of $83.84 million, a price-to-earnings ratio of -1.20 and a beta of 1.60.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). On average, equities analysts expect that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Hedge Funds Weigh In On Regulus Therapeutics

A number of large investors have recently modified their holdings of the stock. Creative Planning acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $26,000. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics in the 3rd quarter valued at $33,000. Jane Street Group LLC bought a new stake in shares of Regulus Therapeutics during the third quarter worth $46,000. JPMorgan Chase & Co. lifted its stake in shares of Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 52,059 shares during the period. Finally, Barclays PLC boosted its holdings in Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after acquiring an additional 62,549 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.